Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that can become life-threatening when paired with other metabolic diseases like diabetes. After years of failed clinical trials, U.S. regulators finally approved the first drug to tackle MASH earlier this year. When the body begins to store fat in the liver, it can cause inflammation resulting in liver disease. And 20% of those who have metabolic dysfunction-associated steatotic liver disease (MASLD) – chronic liver disease that affects a quarter of the adult U.S. population – will develop MASH. California-based Akero Therapeutics is also in pursuit of MASH drug success.

Source: Los Angeles Times June 20, 2024 01:02 UTC